-+ 0.00%
-+ 0.00%
-+ 0.00%

Oracle (ORCL) And The Valuation Debate Behind Its Federal Health Data Win

Simply Wall St·11/17/2026 08:11:32
Listen to the news

Oracle (ORCL) is back in focus after Oracle Health said the U.S. Department of Veterans Affairs and the Department of War joined its Qualified Health Information Network, highlighting the group’s expanding role in federal health data infrastructure.

For investors, the latest Oracle Health win lands against a rough tape. The share price has retreated over recent months, with a 30 day share price return of 7.13% and a 90 day share price return of 16.6% in decline, contributing to a year to date share price return of 39.15% lower and a 1 year total shareholder return of 45.11% lower, even though the 3 year and 5 year total shareholder returns remain positive at 5.52% and 34.68%.

Scan beyond Oracle and see how other AI infrastructure players are priced today with our curated list of 53 AI infrastructure stocks

Oracle now sits at an awkward intersection between a business signing large cloud and health deals and a share price that has sharply reset. Is the current valuation pointing to pessimism overshooting fundamentals, or simply sentiment catching up with them?

Most Popular Narrative: 38% Undervalued

On the Simply Wall St Community fair value of $192.59, Oracle shares at $119.09 sit well below the narrative estimate, and according to andre_santos, a Simply Wall St Community investor who wrote the narrative, that gap rests on a detailed multi model valuation.

To calculate the intrinsic value of the company I will use multiple methods. Discounted Cash Flows DCF, EPS Growth, Historical P/S, Historical EV/EBITDA, and Historical P/E.

See why 115 investors see Oracle as 38% undervalued.

Result: Fair Value of $192.59 (UNDERVALUED)

Still, the narrative leans on assumptions that Oracle can justify a US$390.8b valuation while carrying an estimated cost of capital of 12.00% and a narrow moat rating.

Find out about the key risks to this Oracle narrative.

Next Steps

Mixed on Oracle so far, or already leaning one way? Move quickly to test that view against the underlying data, then weigh up the 4 key rewards and 3 important warning signs.

Looking for more ideas beyond Oracle?

If Oracle has sharpened your focus on where capital goes next, do not stop here. Broader opportunity often sits just one thoughtful screen away.

  • Target potential mispricings by scanning our data driven list of 35 high quality undervalued stocks that pair quality fundamentals with compressed expectations.
  • Lock in cash flow visibility by reviewing a curated group of income focused 6 dividend fortresses that may help steady your overall portfolio ride.
  • Guard against unpleasant surprises by filtering for a 29 resilient stocks with low risk scores that emphasizes resilient balance sheets and more measured volatility.